REG - Polarean Imaging PLC - Total Voting Rights

Polarean ImagingAnnouncement

30/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211130:nRSd9439Ta&default-theme=true

RNS Number : 9439T  Polarean Imaging PLC  30 November 2021

Polarean Imaging Plc

("Polarean" or the "Company")

 

Total Voting Rights

 

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company,
with a proprietary drug‑device combination product using hyperpolarised
xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary
medicine, announces that the total number of shares in issue and total voting
rights as at the date of this announcement is 209,139,966 ordinary shares of
£0.00037 each.

 

The total issued share capital of the Company consists of 209,139,966 Ordinary
Shares. This number may be used by Shareholders as the denominator for the
calculation by which they will determine if they are required to notify their
interest in, or change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

 Polarean Imaging plc                                     www.polarean.com / www.polarean-ir.com
 Richard Hullihen, Chief Executive Officer                Via Walbrook PR
 Jonathan Allis, Chairman

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)            +44 (0)20 7710 7600
 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment
 Banking)
 Nick Adams / Fred Walsh (Corporate Broking)

 Walbrook PR        Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Paul McManus / Anna Dunphy            Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 

About Polarean (www.polarean.com (http://www.polarean.com) )

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the
"Group") are revenue generating, medical drug-device combination companies
operating in the high resolution functional magnetic resonance imaging market.

 

The Group develops equipment that enables existing MRI systems to achieve an
improved level of pulmonary function imaging and specialises in the use of
hyperpolarised Xenon gas ((129)Xe) as an imaging agent to visualise
ventilation and gas exchange regionally in the smallest airways of the lungs,
the tissue barrier between the lung and the bloodstream and in the pulmonary
vasculature. Xenon gas exhibits solubility and signal properties that enable
it to be imaged within other tissues and organs.

 

The Group operates in an area of significant unmet medical need and the
Group's technology provides a novel diagnostic approach, offering a
non-invasive and radiation-free functional imaging platform which is more
accurate and less harmful to the patient than current methods. The annual
burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency
(RF) coils which are a required component for imaging (129)Xe in the MRI
system. The development of these coils by the Group facilitates the adoption
of the Xenon technology by providing application-specific RF coils which
optimise the imaging of (129)Xe in MRI equipment for use as a medical
diagnostic as well as a method of monitoring the efficacy of therapeutic
intervention.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAXFNADSFFFA